A novel PARP inhibitor, ion channel modulation and AD therapies.
On the fourth and final day of the EPHAR congress, ion channel modulation was the topic for two symposia and plenary lectures. The potential of dual potassium and calcium channel blockers as antiarrhythmics was discussed, amongst other applications for ion channel modifiers. Several presentations were dedicated to the disclosure of a novel PARP inhibitor, BGP15, developed at the University Medical School of Pecs in Hungary. This compound is emerging as a promising potential anti-ischemic and a chemoprotective agent. The treatment of Alzheimer's disease (AD) was the subject of further discussions; a detailed presentation was given by a psychiatrist from the US, describing the treatment regimens favored in her clinic, as well as a complete review of currently available and potentially new AD therapies.
Worker
C
C
Current Drugs Ltd, Middlesex House, 34-42 Cleveland Street, London, W1P 6LB, UK. charlotte@cursci.co.uk